3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Graft vs Host Disease
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
COVID-19
1
Brain Neoplasms
1
Interventions
Sunitinib
20
Nivolumab
16
cabozantinib
12
Sorafenib
12
pembrolizumab
11
pazopanib
9
Ipilimumab
9
Interferon-alpha
9
belzutifan
8
Everolimus
8
lenvatinib
7
Bevacizumab
7
aldesleukin
6
Magnetic Resonance Spectroscopy
6
Axitinib
6
atezolizumab
5
Interferon alpha-2
4
temsirolimus
3
Specimen Handling
3
Radiosurgery
3
Nephrectomy
3
Interleukin-2
3
tivozanib
2
durvalumab
2
avelumab
2
Saline Solution
2
G250 monoclonal antibody
2
Fluorouracil
2
Chemotherapy, Adjuvant
2
CTLA-4 Antigen
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Renal Cell
×
Atorvastatin
×
Clear all
NCT05796973
2025-06-27
MOVES
Tampere University Hospital
Phase 3
Recruiting
240 enrolled